Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2017 Jun;79(6):1273-1276. doi: 10.1007/s00280-017-3320-y. Epub 2017 Apr 27.

Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.

Author information

1
Oncologie, CHU Besançon, 25030, Besançon cedex, France. a.thieryvuillemin@mac.com.
2
INSERM, UMR1098, 25020, Besançon cedex, France. a.thieryvuillemin@mac.com.
3
Université de Franche-Comté, UMR1098, SFR IBCT, 25020, Besançon, France. a.thieryvuillemin@mac.com.
4
Medical Oncology, CHU Jean MINJOZ, Boulevard Fleming, 25030, Besancon, France. a.thieryvuillemin@mac.com.
5
Oncologie, CHU Besançon, 25030, Besançon cedex, France.
6
Université de Franche-Comté, UMR1098, SFR IBCT, 25020, Besançon, France.
7
Nephrology Unit, CHU Besançon, 25030, Besançon cedex, France.
8
Pharmacology Unit, CHU Pellegrin, Bordeaux, France.
9
INSERM, UMR1098, 25020, Besançon cedex, France.
10
Pharmacology Unit, CHU Besançon, 25030, Besançon cedex, France.

Abstract

Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been published on that problematic. This is the first publication discussing the assessment of axitinib PK for a patient undergoing HD. Our results suggest that there is no influence of HD on axitinib blood concentration. Interestingly, the membranes used are common and represent around 90% of the membranes used in routine for HD. Our data are also reassuring both from activity and from safety perspectives. In that case, axitinib administered at a dose of 6 mg twice a day was well tolerated and allowed 12 months of disease control. These results are in line with previous publications discussing other anti-angiogenic tyrosine kinase inhibitors pharmacokinetics, safety and activity among patients with metastatic RCC undergoing hemodialysis.

KEYWORDS:

Axitinib; Hemodialysis; Pharmacokinetic; Renal cell carcinoma; Renal failure

PMID:
28451830
DOI:
10.1007/s00280-017-3320-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center